2024 Q1 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on […]
Overview of AI in Biotech Locust Walk’s Overview of AI in Biotech report discusses how AI has profoundly impacted drug
Podcast: Play in new window | Download (Duration: 35:36 — 81.5MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk’s Geoff Meyerson welcomes Kendalle Burlin O’Connell, Esq., CEO and President of MassBio, the nation’s pioneering biotechnology trade
Podcast: Play in new window | Download (Duration: 11:09 — 25.5MB)
Subscribe: Apple Podcasts | Spotify | RSS
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: We invite you to
2023 Year-In-Review Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on
Podcast: Play in new window | Download (Duration: 32:27 — 74.3MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Soufiane Aboulhouda, Co-Founder and Chairman of the Board of Nucleate, a global non-profit dedicated to
Podcast: Play in new window | Download (Duration: 1:00:20 — 138.1MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk‘s Daniel Brog welcomes with Shehnaaz Suliman, M.D., CEO of ReCode Therapeutics, a clinical-stage genetic medicines company using its
Podcast: Play in new window | Download (Duration: 54:18 — 124.3MB)
Subscribe: Apple Podcasts | Spotify | RSS
On this episode of Biotalk, Locust Walk‘s Geoff Meyerson welcomes Errik Anderson, CEO and Founder of Alloy Therapeutics, to the podcast. Alloy is a trailblazing
Podcast: Play in new window | Download (Duration: 13:59 — 32.0MB)
Subscribe: Apple Podcasts | Spotify | RSS
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, delves into our 2023 Q3 Report: Global Trends in Biopharma Transactions Report.
2023 Q3 Report: Global Trends in Biopharma Transactions Each quarter, Locust Walk’s deal team compiles key statistics and trends on